Episode 870: What Sets Theralase Technologies’ ($TLT.V | $TLTFF) Ruvidar® Apart in Bladder Cancer Treatment

This interview is disseminated on behalf of Theralase Technologies Inc.Theralase Technologies Inc. (TSXV: TLT | OTCQB: TLTFF) Chairman, President, and CEO Roger Dumoulin-White, B.Sc, P. Eng. discusses the company’s clinical-stage cancer treatment technology and its development for patients with BCG-unresponsive non-muscle invasive bladder cancer. The interview covers interim Phase II clinical study results for Ruvidar®, including response durability and safety, as well as the potential advantages of Theralase’s drug and proprietary light activation system.Learn more: https://theralase.com/Watch the full YouTube interview here: https://www.youtube.com/watch?v=sb-_w3PoR_kAnd follow us to stay updated: https://www.youtube.com/@stockstowatchofficial